醫藥品原料藥 (API)的全球市場 (不同製造工程，API類別，醫藥品類別，各治療領域):產業分析，市場規模·佔有率·成長·趨勢·預測

本報告提供全球醫藥品原料藥 (API) 市場相關調查，彙整市場收益的實際成果·預測，市場促進要素·阻礙要素分析，製造手法·API的種類·醫藥品的種類·治療領域及地區別的分析與預測，競爭情形，主要企業簡介等資訊，為您概述為以下內容。

第1章 序論

第2章 摘要整理

第3章 市場概要

• 簡介
• 市場動態
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
• 活動的影響度分析
• 價值鏈分析
• 波特的五力分析
• 市場向心力分析:各地區
• 競爭環境:主要企業的市場規模

第4章 全球API (醫藥品原料藥) 市場:不同製造工程

• 簡介
• 自家製造 (公司內部生產):市場收益額 (以金額為準，總計11年份)
• 受託製造 (外包生產):市場收益額 (以金額為準，總計11年份)

第5章 全球API市場:API類別

• 簡介
• 合成化學API:市場收益額 (以金額為準，總計11年份)
• 生技藥品API:市場收益額 (以金額為準，總計11年份)

第6章 全球API市場:醫藥品類別

• 簡介
• 品牌處方藥API:市場收益額 (以金額為準，總計11年份)
• 非專利處方藥API:市場收益額 (以金額為準，總計11年份)
• 成藥 (OTC) 用API:市場收益額 (以金額為準，總計11年份)

第7章 全球API市場:各治療領域

• 簡介
• 心血管疾病治療藥用:市場收益額 (以金額為準，總計11年份)
• 代謝障礙治療藥用:市場收益額 (以金額為準，總計11年份)
• 神經病變治療藥用:市場收益額 (以金額為準，總計11年份)
• 抗癌劑用:市場收益額 (以金額為準，總計11年份)
• 肌肉骨骼障礙治療藥用:市場收益額 (以金額為準，總計11年份)
• NSAID (非類固醇系抗發炎藥) 治療藥用:市場收益額 (以金額為準，總計11年份)
• 其他的治療藥用:市場收益額 (以金額為準，總計11年份)

第8章 全球API市場:各地區

• 簡介
• 北美的API市場:各國 (以金額為準，總計11年份)
  • 美國，加拿大
• 亞太地區的API市場收益額:各國 (以金額為準，總計11年份)
  • 中國，日本，印度等
• 歐洲的API市場:各國 (以金額為準，總計11年份)
  • 德國，英國等
• 其他的國? (RoW)

第9章 建議

• 在標的地區透過企業收購擴張生產能力
• 獲得特定API分子領域的成本主導權

第10章 企業簡介

• Allergan plc
• BASF SE
• Boehringer Ingelheim GmbH
• Cambrex Corporation
• Dr. Reddy's Laboratories
• Lonza Group
• Mylan N.V.
• Pfizer, Inc.
• Sandoz (Novartis AG)
• Teva Pharmaceutical Industries Ltd.
• WuXi AppTec

Title:
Active Pharmaceutical Ingredients (API) Market (Manufacturer - In house API Manufacturing, API Contract Manufacturing; APIs - Synthetic Chemical API, Biotech or Biological API, Plant Extracts API, High-potency API, Classical Fermentation API; Drug - Branded or Innovative Prescription Drugs, Generic Prescription Drugs, OTC (Over-the-counter) Drugs; Therapeutic - Anti-infective Drugs, Metabolic Disorders Drugs, Cardiovascular Drugs, Respiratory Diseases Drugs) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026.

Active Pharmaceutical Ingredients (API) Market - Overview

Biotech/biological APIs have witnessed constant technological evolution, owing to a shift from synthetic chemical APIs to biotech/biological APIs in the global active pharmaceutical ingredients market.

Rise in demand for new drugs at a low cost and entry of domestic and global companies in the APIs market have led to innovative product offerings with new and advanced techniques. Any substance or combination of substances used in a finished pharmaceutical product (FPP) is known as active pharmaceutical ingredients (API). A finished dose of any drug is a combination of active pharmaceutical ingredients and excipients. An excipient is an inactive substance in a drug dose.

High-potency active pharmaceutical ingredients (HPAPIs) and antibody-drug conjugates are recent innovations in the market and require a special manufacturing set up. Most of these drugs are used in oncology. A large number of patents for small molecule APIs are expected to expire in the next few years, with many drugs losing patent protection in 2018. This is estimates to unlock a significant market opportunity for generic drug manufacturers, resulting in augmented demand for APIs. Large pharmaceutical companies are scaling down their small molecule manufacturing facilities to focus on biologic drugs, thereby presenting greater opportunities for contract manufacturing companies, particularly in Asia.

A key trend of collaborations and acquisitions of related companies to increase geographic presence has been observed in the last few years. For instance, in July 2017, Sun Pharmaceutical Industries Ltd. Entered into a long-term manufacturing agreement with Samsung BioLogics for the manufacture of Ilumya.

The global active pharmaceutical ingredients market has been broadly segmented based on manufacturer, APIs, drug, therapeutic, and region. In terms of manufacturer, the global market has been classified into in-house API manufacturing and API contract manufacturing. The in-house API manufacturing segment accounted for a key share of the global market, in terms of revenue, in 2017. The API contract manufacturing segment is estimated to expand at a significant growth rate during the forecast period. Consequently, the segment is estimated to gain significant market share by the end of 2026.

In terms of region, the global active pharmaceutical ingredients market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to lose market share by the end of 2026. The market in North America is primarily driven by a rapid increase in the geriatric population, high adoption of new drugs, and rise in group dental practices in the U.S.. The market in Asia Pacific is projected to expand at a rapid pace during the forecast period. In Asia Pacific, Japan dominated the active pharmaceutical ingredients market, while the market in China is estimated to expand at a prominent CAGR during the forecast period. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major players operating in global active pharmaceutical ingredients market include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Pfizer Inc., Boehringer Ingelheim International GmbH., Merck & Co., Inc., Novartis AG, F. Hoffmann-La Roche Ltd, and Bayer AG..

The global active pharmaceutical ingredients market has been segmented as given below:

• Global Active Pharmaceutical Ingredients (API) Market, by Manufacturer
• In-house API Manufacturing
• API Contract Manufacturing
• Global Active Pharmaceutical Ingredients (API) Market, by APIs
• Synthetic Chemical API
• Biotech/Biological API
• Plant Extracts API
• High-potency API
• Classical Fermentation API
• Global Active Pharmaceutical Ingredients (API) Market, by Drug
• Branded or Innovative Prescription Drugs
• Generic Prescription Drugs
• over-the-counter (OTC) Drugs
• Others
• Global Active Pharmaceutical Ingredients (API) Market, by Therapeutic
• Anti-infective Drugs
• Metabolic Disorders Drugs
• Cardiovascular Drugs
• Oncology Drugs
• Central Nervous System Drugs
• Respiratory Diseases Drugs
• Others
• Global Active Pharmaceutical Ingredients (API) Market, by Region
• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• GCC
• South Africa
• Israel
• Rest of Middle East & Africa

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Active Pharmaceutical Ingredients (API)

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Type of Manufacturers Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
    • 4.3.1.1. Increase in Abbreviated New Drug Applications (ANDA) in the Recent Past Boosted the Demand for APIs
    • 4.3.1.2. Increasing Government Prioritization for Biomedical Innovation
    • 4.3.1.3. Increase in Drug Master File (DMF) Filing from Indian and Chinese Companies Indicates a Rapid API market growth
    • 4.3.1.4. Increasing Incidence of Acute and Chronic Diseases
    • 4.3.1.5. Increasing Biopharmaceuticals Uptake Globally
  • 4.3.2. Restraints
    • 4.3.2.1.Strict European Union Regulatory Policies Restraining Market Growth
    • 4.3.2.2. Unfavorable Drug Price Control Policies
  • 4.3.3. Opportunities
  • 4.3.4. Key Trends
    • 4.3.4.1. Biologics Expected to be Key Pipeline Trend
    • 4.3.4.2. Increase in Focus on Research & Development
    • 4.3.4.3. Shift from Branded to Generics
    • 4.3.4.4. Governments Encouraging Development of Orphan Drugs
• 4.4. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, 2016-2026
  • 4.4.1. Market Revenue Projections (US$ Mn)
• 4.5. Porter's Five Force Analysis

5. Market Outlook

• 5.1. Value Chain Analysis
• 5.2. Patent Expiry of Major Drugs in 2018
• 5.3. Patent Expiry of Major Drugs in 2019 & 2020

6. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Type of Manufacturers

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast by Type of Manufacturers, 2016-2026
  • 6.3.1. In-house API Manufacturing
  • 6.3.2. API Contract Manufacturing
• 6.4. Market Attractiveness, by Type of Manufacturers

7. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Type of APIs

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Type of APIs, 2016-2026
  • 7.3.1. Synthetic Chemical API
  • 7.3.2. Biotech/Biological API
  • 7.3.3. Plant Extracts API
  • 7.3.4. High-potency API
  • 7.3.5. Classical Fermentation API
• 7.4. Market Attractiveness, by Type of APIs

8. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Type of Drug

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Type of Drug, 2016-2026
  • 8.3.1. Branded or Innovative Prescription Drugs
  • 8.3.2. Generic Prescription Drugs
  • 8.3.3. Over-the-counter (OTC) Drugs
  • 8.3.4. Others
• 8.4. Market Attractiveness, by Type of Drug

9. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Therapeutic

• 9.1. Introduction & Definition
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by Therapeutic, 2016-2026
  • 9.3.1. Anti-infective Drugs
  • 9.3.2. Metabolic Disorders Drugs
  • 9.3.3. Cardiovascular Drugs
  • 9.3.4. Oncology Drugs
  • 9.3.5. Central Nervous System Drugs
  • 9.3.6. Respiratory Diseases Drugs
  • 9.3.7. Others
• 9.4. Market Attractiveness, by Therapeutic

10. Global Active Pharmaceutical Ingredients (API) Analysis and Forecasts, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast by Region
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness, by Region

11. North America Active Pharmaceutical Ingredients (API) Analysis and Forecast

• 11.1.Introduction
  • 11.1.1. Key Findings
• 11.2.Market Value Forecast, by Type of Manufacturers, 2016-2026
  • 11.2.1. In-house API Manufacturing
  • 11.2.2. API Contract Manufacturing
• 11.3.Market Value Forecast, by Type of APIs, 2016-2026
  • 11.3.1. Synthetic Chemical API
  • 11.3.2. Biotech/Biological API
  • 11.3.3. Plant Extracts API
  • 11.3.4. High-potency API
  • 11.3.5. Classical Fermentation API
• 11.4.Market Value Forecast, by Type of Drug, 2016-2026
  • 11.4.1. Branded or Innovative Prescription Drugs
  • 11.4.2. Generic Prescription Drugs
  • 11.4.3. over-the-counter (OTC) Drugs
  • 11.4.4. Others
• 11.5.Market Value Forecast, by Therapeutic, 2016-2026
  • 11.5.1. Anti-infective Drugs
  • 11.5.2. Metabolic Disorders Drugs
  • 11.5.3. Cardiovascular Drugs
  • 11.5.4. Oncology Drugs
  • 11.5.5. Central Nervous System Drugs
  • 11.5.6. Respiratory Diseases Drugs
  • 11.5.7. Others
• 11.6.Market Value Forecast, by Country, 2016-2026
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7.Market Attractiveness Analysis
  • 11.7.1. By Type of Manufacturers
  • 11.7.2. By Type of APIs
  • 11.7.3. By Type of Drug
  • 11.7.4. By Therapeutic
  • 11.7.5. By Country

12. Europe Active Pharmaceutical Ingredients (API) Analysis and Forecast

• 12.1.Introduction
  • 12.1.1. Key Findings
• 12.2.Market Value Forecast, by Type of Manufacturers, 2016-2026
  • 12.2.1. In-house API Manufacturing
  • 12.2.2. API Contract Manufacturing
• 12.3.Market Value Forecast, by Type of APIs, 2016-2026
  • 12.3.1. Synthetic Chemical API
  • 12.3.2. Biotech/Biological API
  • 12.3.3. Plant Extracts API
  • 12.3.4. High-potency API
  • 12.3.5. Classical Fermentation API
• 12.4.Market Value Forecast, by Type of Drug, 2016-2026
  • 12.4.1. Branded or Innovative Prescription Drugs
  • 12.4.2. Generic Prescription Drugs
  • 12.4.3. Over-the-counter (OTC) Drugs
  • 12.4.4. Others
• 12.5.Market Value Forecast, by Therapeutic, 2016-2026
  • 12.5.1. Anti-infective Drugs
  • 12.5.2. Metabolic Disorders Drugs
  • 12.5.3. Cardiovascular Drugs
  • 12.5.4. Oncology Drugs
  • 12.5.5. Central Nervous System Drugs
  • 12.5.6. Respiratory Diseases Drugs
  • 12.5.7. Others
• 12.6.Market Value Forecast, by Country/Sub-region, 2016-2026
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Spain
  • 12.6.5. Italy
  • 12.6.6. Rest of Europe
• 12.7.Market Attractiveness Analysis
  • 12.7.1. By Type of Manufacturers
  • 12.7.2. By Type of APIs
  • 12.7.3. By Type of Drug
  • 12.7.4. By Therapeutic
  • 12.7.5. By Country/Sub-region

13. Asia Pacific Active Pharmaceutical Ingredients (API) Analysis and Forecast

• 13.1.Introduction
  • 13.1.1. Key Findings
• 13.2.Market Value Forecast, by Type of Manufacturers, 2016-2026
  • 13.2.1. In-house API Manufacturing
  • 13.2.2. API Contract Manufacturing
• 13.3.Market Value Forecast, by Type of APIs, 2016-2026
  • 13.3.1. Synthetic Chemical API
  • 13.3.2. Biotech/Biological API
  • 13.3.3. Plant Extracts API
  • 13.3.4. High-potency API
  • 13.3.5. Classical Fermentation API
• 13.4.Market Value Forecast, by Type of Drug, 2016-2026
  • 13.4.1. Branded or Innovative Prescription Drugs
  • 13.4.2. Generic Prescription Drugs
  • 13.4.3. Over-the-counter (OTC) Drugs
  • 13.4.4. Others
• 13.5.Market Value Forecast, by Therapeutic, 2016-2026
  • 13.5.1. Anti-infective Drugs
  • 13.5.2. Metabolic Disorders Drugs
  • 13.5.3. Cardiovascular Drugs
  • 13.5.4. Oncology Drugs
  • 13.5.5. Central Nervous System Drugs
  • 13.5.6. Respiratory Diseases Drugs
  • 13.5.7. Others
• 13.6.Market Value Forecast, by Country/Sub-region, 2016-2026
  • 13.6.1. China
  • 13.6.2. Japan
  • 13.6.3. India
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7.Market Attractiveness Analysis
  • 13.7.1. By Type of Manufacturers
  • 13.7.2. By Type of APIs
  • 13.7.3. By Type of Drug
  • 13.7.4. By Therapeutic
  • 13.7.5. By Country/Sub-region

14. Latin America Active Pharmaceutical Ingredients (API) Analysis and Forecast

• 14.1.Introduction
  • 14.1.1. Key Findings
• 14.2.Market Value Forecast, by Type of Manufacturers, 2016-2026
  • 14.2.1. In-house API Manufacturing
  • 14.2.2. API Contract Manufacturing
• 14.3.Market Value Forecast, by Type of APIs, 2016-2026
  • 14.3.1. Synthetic Chemical API
  • 14.3.2. Biotech/Biological API
  • 14.3.3. Plant Extracts API
  • 14.3.4. High-potency API
  • 14.3.5. Classical Fermentation API
• 14.4.Market Value Forecast, by Type of Drug, 2016-2026
  • 14.4.1. Branded or Innovative Prescription Drugs
  • 14.4.2. Generic Prescription Drugs
  • 14.4.3. Over-the-counter (OTC) Drugs
  • 14.4.4. Others
• 14.5.Market Value Forecast, by Therapeutic, 2016-2026
  • 14.5.1. Anti-infective Drugs
  • 14.5.2. Metabolic Disorders Drugs
  • 14.5.3. Cardiovascular Drugs
  • 14.5.4. Oncology Drugs
  • 14.5.5. Central Nervous System Drugs
  • 14.5.6. Respiratory Diseases Drugs
  • 14.5.7. Others
• 14.6.Market Value Forecast, by Country/Sub-region, 2016-2026
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7.Market Attractiveness Analysis
  • 14.7.1. By Type of Manufacturers
  • 14.7.2. By Type of APIs
  • 14.7.3. By Type of Drug
  • 14.7.4. By Therapeutic
  • 14.7.5. By Country/Sub-region

15. Middle East & Africa Active Pharmaceutical Ingredients (API) Analysis and Forecast

• 15.1.Introduction
  • 15.1.1. Key Findings
  • 15.2.Market Value Forecast, by Type of Manufacturers, 2016-2026
  • 15.2.1. In-house API Manufacturing
  • 15.2.2. API Contract Manufacturing
• 15.3.Market Value Forecast, by Type of APIs, 2016-2026
  • 15.3.1. Synthetic Chemical API
  • 15.3.2. Biotech/Biological API
  • 15.3.3. Plant Extracts API
  • 15.3.4. High-potency API
  • 15.3.5. Classical Fermentation API
• 15.4.Market Value Forecast, by Type of Drug, 2016-2026
  • 15.4.1. Branded or Innovative Prescription Drugs
  • 15.4.2. Generic Prescription Drugs
  • 15.4.3. Over-the-counter (OTC) Drugs
  • 15.4.4. Others
• 15.5.Market Value Forecast, by Therapeutic, 2016-2026
  • 15.5.1. Anti-infective Drugs
  • 15.5.2. Metabolic Disorders Drugs
  • 15.5.3. Cardiovascular Drugs
  • 15.5.4. Oncology Drugs
  • 15.5.5. Central Nervous System Drugs
  • 15.5.6. Respiratory Diseases Drugs
  • 15.5.7. Others
• 15.6.Market Value Forecast, by Country/Sub-region, 2016-2026
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Israel
  • 15.6.4. Rest of Middle East & Africa
• 15.7.Market Attractiveness Analysis
  • 15.7.1. By Type of Manufacturers
  • 15.7.2. By Type of APIs
  • 15.7.3. By Type of Drug
  • 15.7.4. By Therapeutic
  • 15.7.5. By Country/Sub-region

16. Competition Landscape

• 16.1.Market Player - Competition Matrix (By Tier and Size of companies)
• 16.2.Market Share Analysis, by Company (2017)
• 16.5. Company Profiles
  • 16.5.1. Teva Pharmaceutical Industries Ltd.
  • 16.5.2. Sun Pharmaceutical Industries Ltd.
  • 16.5.3. Aurobindo Pharma
  • 16.5.4. Pfizer Inc.
  • 16.5.5. Boehringer Ingelheim International GmbH.
  • 16.5.6. Merck & Co., Inc.
  • 16.5.7. Novartis AG
  • 16.5.8. F. Hoffmann-La Roche Ltd
  • 16.5.9. Bayer AG
  • 16.5.10. Others

List of Tables

• Table 01: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Manufacturer, 2016-2026
• Table 02: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of APIs, 2016-2026
• Table 03: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Drug, 2016-2026
• Table 04: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Therapeutic, 2016-2026
• Table 05: Global Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn) Forecast, by Region, 2016-2026
• Table 06: Patent Expiry of Major Drugs in 2018
• Table 07: Patent Expiry of Major Drugs in 2019 & 2020
• Table 08 : North America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Manufacturer, 2016-2026
• Table 09 : North America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of APIs, 2016-2026
• Table 10 : North America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Drug, 2016-2026
• Table 11 : North America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Therapeutic, 2016-2026
• Table 12 : North America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn) Forecast, by Country 2016-2026
• Table 13 : Europe Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Manufacturer, 2016-2026
• Table 14 : Europe Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of APIs, 2016-2026
• Table 15 : Europe Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Drug, 2016-2026
• Table 16 : Europe Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Therapeutic, 2016-2026
• Table 17 : Europe Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
• Table 18 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Manufacturers, 2016-2026
• Table 19 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of APIs, 2016-2026
• Table 20 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Drug, 2016-2026
• Table 21 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Therapeutic, 2016-2026
• Table 22 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
• Table 23 : Latin America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Manufacturers, 2016-2026
• Table 24 : Latin America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of APIs, 2016-2026
• Table 25 : Latin America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Drug, 2016-2026
• Table 26 : Latin America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Therapeutic, 2016-2026
• Table 27 : Latin America Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
• Table 28 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Manufacturers, 2016-2026
• Table 29 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of APIs, 2016-2026
• Table 30 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Type of Drug, 2016-2026
• Table 31 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, by Therapeutic, 2016-2026
• Table 32 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2016-2026

List of Figures

• Figure 01: Active Pharmaceutical Ingredients (API) Market Snapshot
• Figure 02: Executive Summary
• Figure 03: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Mn), CAGR (%), and Market Share (%), by Region, 2018 and 2026
• Figure 04: Key Market Developments
• Figure 05: Global Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2016-2026
• Figure 06: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Manufacturers, 2018 and 2026
• Figure 07: Global Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Manufacturers, 2018-2026
• Figure 08: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Type of APIs, 2018 and 2026
• Figure 09: Global Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of APIs, 2018-2026
• Figure 10: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Drug, 2018 and 2026
• Figure 11: Global Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Drug, 2018-2026
• Figure 12: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Therapeutic, 2018 and 2026
• Figure 13: Global Active Pharmaceutical Ingredients (API) Market Attractiveness, by Therapeutic, 2018-2026
• Figure 14: Global Active Pharmaceutical Ingredients (API) Market Value Share, by Region, 2018 and 2026
• Figure 15: Global Active Pharmaceutical Ingredients (API) Market Attractiveness, by Region, 2018-2026
• Figure 16 : North America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2016-2026
• Figure 17 : North America Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Manufacturers, 2018 and 2026
• Figure 18 : North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Manufacturers, 2018-2026
• Figure 19 : North America Active Pharmaceutical Ingredients (API) Market Value Share, by Type of APIs, 2018 and 2026
• Figure 20 : North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of APIs, 2018-2026
• Figure 21 : North America Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Drug, 2018 and 2026
• Figure 22 : North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Drug, 2018-2026
• Figure 23 : North America Active Pharmaceutical Ingredients (API) Market Value Share, by Therapeutic, 2018 and 2026
• Figure 24 : North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Therapeutic, 2018-2026
• Figure 25 : North America Active Pharmaceutical Ingredients (API) Market Value Share, by Country, 2018 and 2026
• Figure 26 : North America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country, 2018-2026
• Figure 27 : Europe Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2016-2026
• Figure 28 : Europe Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Manufacturers, 2018 and 2026
• Figure 29 : Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Manufacturers, 2018-2026
• Figure 30 : Europe Active Pharmaceutical Ingredients (API) Market Value Share, by Type of APIs, 2018 and 2026
• Figure 31 : Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of APIs, 2018-2026
• Figure 32 : Europe Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Drug, 2018 and 2026
• Figure 33 : Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Drug, 2018-2026
• Figure 34 : Europe Active Pharmaceutical Ingredients (API) Market Value Share, by Therapeutic, 2018 and 2026
• Figure 35 : Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Therapeutic, 2018-2026
• Figure 36 : Europe Active Pharmaceutical Ingredients (API) Market Value Share, by Country/Sub-region, 2018 and 2026
• Figure 37 : Europe Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country/Sub-region, 2018-2026
• Figure 38 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2016-2026
• Figure 39 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Manufacturers, 2018 and 2026
• Figure 40 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Manufacturers, 2018-2026
• Figure 41 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share, by Type of APIs, 2018 and 2026
• Figure 42 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of APIs, 2018-2026
• Figure 43 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Drug, 2018 and 2026
• Figure 44 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Drug, 2018-2026
• Figure 45 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share, by Therapeutic, 2018 and 2026
• Figure 46 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Therapeutic, 2018-2026
• Figure 47 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Value Share, by Country/Sub-region, 2018 and 2026
• Figure 48 : Asia Pacific Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country/Sub-region, 2018-2026
• Figure 49 : Latin America Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2016-2026
• Figure 50 : Latin America Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Manufacturers, 2018 and 2026
• Figure 51 : Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Manufacturers, 2018-2026
• Figure 52 : Latin America Active Pharmaceutical Ingredients (API) Market Value Share, by Type of APIs, 2018 and 2026
• Figure 53 : Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of APIs, 2018-2026
• Figure 54 : Latin America Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Drug, 2018 and 2026
• Figure 55 : Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Drug, 2018-2026
• Figure 56 : Latin America Active Pharmaceutical Ingredients (API) Market Value Share, by Therapeutic, 2018 and 2026
• Figure 57 : Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Therapeutic, 2018-2026
• Figure 58 : Latin America Active Pharmaceutical Ingredients (API) Market Value Share, by Country/Sub-region, 2018 and 2026
• Figure 59 : Latin America Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country/Sub-region, 2018-2026
• Figure 60 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value (US$ Mn) Forecast, 2016-2026
• Figure 61 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Manufacturers, 2018 and 2026
• Figure 62 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Manufacturers, 2018-2026
• Figure 63 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share, by Type of APIs, 2018 and 2026
• Figure 64 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of APIs, 2018-2026
• Figure 65 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share, by Type of Drug, 2018 and 2026
• Figure 66 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Type of Drug, 2018-2026
• Figure 67 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share, by Therapeutic, 2018 and 2026
• Figure 68 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Therapeutic, 2018-2026
• Figure 69 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Value Share, by Country/Sub-region, 2018 and 2026
• Figure 70 : Middle East & Africa Active Pharmaceutical Ingredients (API) Market Attractiveness, by Country/Sub-region, 2018-2026